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Brazilian Guidelines for transcranial doppler in children and adolescents with
sickle cell disease
Background: Sickle cell disease is the most common monogenic hereditary disease in Brazil. Although
strokes are one of the main causes of morbidity and mortality in these patients, the use of transcranial
Doppler to identify children at risk is not universally used.
Objective: To develop Brazilian guidelines for the use of transcranial Doppler in sickle cell disease
children and adolescents, so that related health policies can be expanded, and thus contribute to
reduce morbidity and mortality.
Methods: The guidelines were formulated in a consensus meeting of experts in transcranial Doppler
and sickle cell disease. The issues discussed were previously formulated and scientific articles in
databases (MEDLINE, SciELO and Cochrane) were carefully analyzed. The consensus for each
question was obtained by a vote of experts on the specific theme.
Results: Recommendations were made, including indications for the use of transcranial Doppler
according to the sickle cell disease genotype and patients age; the necessary conditions to perform the
exam and its periodicity depending on exam results; the criteria for the indication of blood transfusions
and iron chelation therapy; the indication of hydroxyurea; and the therapeutic approach in cases of
conditional transcranial Doppler.
Conclusion: The Brazilian guidelines on the use of transcranial doppler in sickle cell disease patients
may reduce the risk of strokes, and thus reduce the morbidity and mortality and improve the quality
of life of sickle cell disease patients.
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Introduction
Sickle cell disease (SCD) is the most common monogenic hereditary disease in
Brazil occurring predominantly among African descents.(1) (A) The term SCD includes
sickle cell anemia (SCA) the form of the disease that occurs in homozygotes of
hemoglobin S (Hb SS), as well as pathological conditions caused by combinations of
the hemoglobin S gene with other hereditary hemoglobin disorders such as sickle cell
SC disease, Hb S/ß+ thalassemia and Hb S/ß0 thalassemia. Complications of SCD, such
as renal failure, vaso-occlusive crisis, acute chest syndrome and strokes result in a
reduction of 25 to 30 years of life expectancy of SCD patients compared to the general
population.(2) (B)
Recently, several aspects have contributed significantly to the reduction in mortality
in SCD patients. These include the control of infections through immunization and the
prophylactic use of antibiotics during early life; watchfulness and appropriate guidance
for parents or caregivers to recognize early signs of splenic sequestration; the diagnosis
and treatment of acute chest syndrome; and the identification of children at risk for
developing strokes using transcranial doppler (TCD), combined with early use of packed
red blood cell (RBC) transfusions when test results are abnormal.(1) (D)
HEMORIO, with the support of the Ministry of Health in Brazil, the Associação
Brasileira de Hematologia e Hemoterapia, and the Pro-HEMORIO Foundation, decided to
develop the Brazilian guidelines on the use of transcranial doppler in sickle cell disease
patients with the intention of expanding health policies for SCD and to contribute in reducing
morbidity and mortality resulting from this pathology. This work was developed in line with
the National Newborn Screening Program which guarantees universal access of newborns
to screening for hemoglobinopathies, and Government decree 1391, which establishes
guidelines for the National Policy of Comprehensive Care for People with Sickle Cell Disease
and other Hemoglobinopathies in the Brazilian national healthcare service.(1) (D)
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Methods
A committee of specialists was formed and the
guidelines were formulated in two parallel consensus
meetings. At a consensus meeting of experts on TCD, nine
regional facilitators, reference physicians in their regions on
this theme, discussed the technical issues of the procedure.
Four national facilitators, physicians who are recognized as
experts in these sub-themes, presented the issues and the
supporting scientific evidence. Records of the debate and a
final summary of the findings for each question were
entrusted to two other specialists in TCD. The consensus
meeting was attended by experts in SCD, 26 regional
facilitators who discussed technical matters involving the
indication of TCD and the treatment to be adopted depending
on the different findings of TCD.
The issues discussed at both consensus meetings were
previously formulated by the national facilitators and two
coordinators of the event, all nationally renowned physicians.
Before the meeting, the national facilitators and coordinators
were also responsible for the identification of regional
facilitators assigned to each theme as well as the selection
and distribution of publications to all participants. The
scientific papers were identified from the MEDLINE, SciELO
and Cochrane databases and papers were classified
according to the degree of recommendation and level of
evidence. The following designations were adopted: (A)
highly consistent experimental or observational studies; (B)
less consistent experimental or observational studies; (C)
case reports (uncontrolled studies); (D) opinions without
critical assessment based on consensus, physiologic studies
or animal models. The consensus for each question was
obtained by voting and proposals were accepted even if there
was a maximum of three opposing votes. Abstentions were
not considered opposing votes. All participants had the right
to vote, except for five participants of organizations that
represent SCD carriers.
Results
Genotype of hemoglobinopathies
Recommendation: TCD should be used for primary
prevention of strokes in SCD patients, regardless of the
genotype of the disease, but with priority to those with the
Hb SS and Hb S/ß0talassemia genotypes.
Although the incidence of strokes is higher in patients
with the Hb SS genotype, it should be noted that strokes
also occur in patients with other genotypes. According to a
publication of the Cooperative Study of Sickle Cell Disease
Group, the incidence of strokes (number of  acute events/100
patients/year) is 0.61 for patients with Hb SS, 0.17 for Hb SC,
0.11 for Hb S/ß+ thalassemia and 0.10 for Hb S/ß0 thalassemia.
It is estimated that 11%, 15% and 24% of SCA patients and
2%, 4% and 10% of Hb SC patients develop symptomatic
strokes up to the ages of 20, 30 and 45 years old, respectively.
The acute event may occur spontaneously or after any acute
complication such as, for example, infections. Additionally,
the study showed that the estimated prevalence of strokes
adjusted for age was 4.01% in patients with Hb SS; 2.43% in
Hb S/ß0 thalassemia, 1.29% for Hb S/ß+ thalassemia and 0.84%
for Hb SC.(3) (B)
Given these data, it was deemed appropriate to
recommend TCD as a method of primary prevention for all
SCD patients regardless of genotype. The long-term
monitoring of the population might allow for eventual
determination of various intervals between examinations
according to the genotype of the disease, as well as a
reassessment of the necessity of screening for genotypes
with lower risk, such as Hb SC and Hb S/ß+ thalassemia.
Age of patients
Recommendation: TCD should be used for primary
prevention of strokes in SCD patients aged between two and
16 years of age.
In the publication of the Cooperative Study of Sickle
Cell Disease Group, the overall incidence of the first stroke
among SCD patients was 0.08 acute events/100 patients/year
in under two-year olds; 0.75 in patients between two and five
years old, 0.55 between six and nine years old, 0.30 between
10 and 19 years old, and 0.45 between 20 and 29 years old.(3)
(B) Although over 16-year-old SCD patients may be at
increased risk of strokes, the association between flow
velocity measured by TCD and the risk of strokes was first
demonstrated in the cohort of SCD patients from the Medical
College of Georgia, which involved children between three
and 18 years old.(4,5) (B)
Subsequently the study, Stroke Prevention Trial in
Sickle Cell Anemia (STOP), which included patients with
SCA aged between two and 16 years, confirmed the
predictive value of TCD for strokes in this patient
population(6) (A) and demonstrated that blood transfusions
significantly reduced the risk of strokes among children in
this age range with abnormal TCD.(7,8) (A) Moreover, these
studies established their own parameters for the definition
of abnormal TCD in this cohort of patients.(6,7) (A) Given
the fact that the cerebral blood flow (CBF) and the estimated
speed of this flow (CBFV) measured by TCD, are increased
in anemic conditions due to decreased oxygen transport
capacity of the blood, it was shown that the parameters of
TCD related to stenosis in adults could not be applied to
SCD children, because of the age and the anemia itself.(9)
(B) (10,11) (C)(12) (D)
Thus, considering the relatively low risk of strokes in
under 2-year-old children with SCD; the absence of validated
parameters of abnormal TCD in SCD patients of < 2 years
old and > 18 years old; and lack of evidence to support
transfusion therapy in SCA patients with ages > 16 years,
the consensus recommendation is to perform TCD for
primary prevention in patients aged between two and 16
years old.
Rev Bras Hematol Hemoter. 2011;33(1)                                                                                                                                                           45
Frequency of transcranial doppler
Recommendation: Conventional TCD is the method of
choice and should be repeated frequency according to the
criteria listed in table 1. The examination must be conducted
and interpreted in accordance with the parameters set by the
STOP study.(4,5) (B) The examination should be performed
with the patient awake, afebrile and at least four weeks after
acute events and blood transfusions.
Although the parameters in the STOP study were
arbitrarily defined, the risk categories proved to be excellent
for the stratification of risk of strokes and the decision to
start transfusion therapy.(13) (C) Thus we recommend the
adoption of the STOP study protocol for the indication of
TCD as a primary stroke prevention method in SCD patients.
TCD may vary due to individual physiological factors (such
as sleep, for example) and pathological factors (such as fever,
for example) that increase the CBFV,(12) (D)(13) (C)(14) (B) which
is the reason that it is recommended to defer examinations for
four weeks in such cases.
TCD based on the methodology adopted in the STOP
study included insonation of 15 arterial segments of the Circle
of Willis: the M1 segment of the middle cerebral artery (MCA)
and to check its entire length at 2-mm intervals to the
bifurcation; the bifurcation of the internal carotid artery (ICA);
the distal or terminal ICA, anterior cerebral artery, posterior
cerebral artery, in both transtemporal windows; and the basilar
artery (top or its bifurcation) through the transforaminal
window. The predictive risk factor for strokes according to
the STOP study was determined by the mean maximum speed
of the CBF in segments of MCA, and at the bifurcation and
distal ICA bilaterally. Wave spectral information was not used
in the STOP study and the submandibular and transorbital
windows were not evaluated.(4,5) (B) (7) (A) It should be noted
that very low speeds (< 70 cm/s) may be indicative of severe
stenosis, (13) (C) which is the reason that it is recommended to
repeat the examination after one month, or to examine the
image by medical criteria.
In addition, the meeting considered that it is essential
to use educational interventions to target parents and
caregivers as well as children, about the importance of
conducting systematic TCD examinations as well as the need
for different therapeutic interventions for those at high risk
for strokes.(15) (B)
Conventional TCD versus TCD imaging
As mentioned previously, conventional TCD is the
method of choice for primary stroke prevention in SCD patients
and the test should be performed and interpreted in
accordance with the parameters set by the STOP study.(4,5) (B)
TCD imaging techniques were not investigated in the
STOP study. However, a few scientific papers have been
published using TCD imaging that tried to evaluate and
establish possible correlations between the findings using
this method and data obtained with conventional TCD.
(16,17)(A)(18-20)(B)(21,22)(C)(23)(D) It was observed that the
velocities obtained by TCD imaging ranged from values similar
to conventional TCD to values 20% lower and this variation
depended on the insonation angle.
Thus, the meeting considered that there is not enough
scientific evidence to make any recommendation of cutoff
values for TCD imaging. Services and Institutions that only
have TCD imaging must take into account differences in
speeds that are reported in the literature.(4,5,18-20) (B) (16,17) (A)
(21,22) (C)(23) (D) Some clinical studies provide regression
equations to convert the speed of blood flow from TCD
imaging to corresponding conventional TCD velocities and
Brazilian Guidelines for transcranial doppler in children and adolescents with sickle cell disease
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thus compatible with those used in the STOP study. However,
it must be remembered that such regression equations may
not apply to all TCD imaging devices. It is recommended that
the method employed (conventional TCD or TCD imaging)
should be cited in the report of test results.
RBC transfusion and iron chelation
Recommendation: RBC transfusion regimens of three
to six weeks using exchange transfusion or partial
exsanguinous transfusion is indicated for patients who
present at least two consecutive TCD examinations with
average CBFV> 200 cm/s (Table 1). Phenotyping should be
made for Kell, Kidd, Duffy and MNSs and when possible for
the Lewis, P and Lutheran blood group systems. Always use
samples leucocyted depleted RBC and phenotyped RBCs, in
principle, for the ABO, Rh and Kell systems. It is recommended
that the storage time of RBCs to be transfused does not
exceed seven days and are negative for Hb S. The patient
should be maintained with a maximum Hb level of up to 10 g/dL
and pre-transfusion Hb level less than 50%.
Iron chelation therapy is indicated for patients submitted
to a simple transfusion regimen who have received more than
twenty units of packed red blood cells and who have serum
ferritin concentrations greater than 1000 ng/mL (at least two
measurements under normal conditions) or grade III or IV
hepatic siderosis by liver biopsy or liver iron concentrations
equal to 4 mg/gram dry matter or above by magnetic resonance
imaging (MRI). The therapeutic alternatives include orally
administered deferasirox and subcutaneously administered
deferoxamine.
In the STOP study, 130 of the 1934 participants were 2-
to 16-year-old children who had changed TCD (mean CBFV
> 200 cm/s in one or both of the middle cerebral arteries or the
distal segment of the internal carotid artery in two exams at
an interval of at least two weeks). These children were
randomized into two groups: observation (with occasional
transfusions) and a regular transfusion regimen aiming at
maintaining Hb S below 30%. After 20 months of follow up,
there was one case of a stroke in the 63 children in the
transfusion group versus 11 cases of strokes in 67 children
in the observation group. These results indicate a 92%
reduction in relative risk for the occurrence of strokes
(reduction in the risk of strokes from 10% per year to < 1%
per year). (7) (A) The follow-up of patients undergoing chronic
transfusion regimens for primary prevention of strokes in the
STOP study also showed significant reductions in the levels
of free hemoglobin compared to controls not subjected to
transfusion or only to occasional transfusions. Furthermore,
other markers of hemolysis such as lactate dehydrogenase
and alanine aminotransferase levels were reduced. It is
believed that the increase in circulating hemoglobin and the
reduction in hemolysis with consequent reductions in free
hemoglobin plasma levels increase bioavailability of nitric
oxide and its effects by reducing or preventing endothelial
dysfunction, which would help to explain the role of
transfusions in preventing strokes.(24) (A) Therefore, it is
recommended to start packed red blood cell transfusions
according to the TCD results as described in Table 1.
However, regular blood transfusion regimens can lead
to an accumulation of iron in the body, as physiological
mechanisms to excrete excessive iron are restricted. SCD
Patients appear to suffer tissue damage similar to other
populations of chronically transfused patients, including iron
deposits in the liver, heart and endocrine organs. The
therapeutic alternatives for iron chelation therapy in SCD
patients undergoing blood transfusions include deferoxamine
and deferasirox. (25) (A) (26) (B)
Indication of hydroxyurea
Recommendation: Although the exchange transfusion
regimen is the method of choice for primary prevention of
strokes in SCD patients who are indicated for this procedure,
treatment with hydroxyurea (HU) may be indicated in cases
in which Hb S levels can not be maintained < 50%, in cases of
patients who do not comply to the red blood cell transfusion
regimen, in cases of alloimmunization, in situations that
phenotyped blood is unavailable and in children without
intravenous access.
HU is an antimetabolite that blocks the synthesis of
deoxyribonucleic acid by inhibiting ribonucleotide reductase.
The efficacy of this agent in the treatment of SCD appears to
be related to increased levels of hemoglobin F (which reduces
the formation of hemoglobin S), cytoreduction of neutrophils,
increased water content inside the RBCs, and increased
capacity for deformation and improvement of microvascular
flow of sickle erythrocytes.(27) (D)
Since the classic Multicenter Study of Hydroxyurea
(MSH) study published in 1995 by Charach et al.,(28) (A) and
the data obtained by Steinberg et al.(29) (A) over more than
nine years of follow-up of patients using HU, such as the
reduction in the number and intensity of pain crises,
decreased hospitalization and reduction in mortality, HU has
been recommended in an ever increasing number of cases,
not only for adults but for children from two years of age or
even earlier.
These are cheap, easy-to-use oral medications with
few serious adverse effects. However, one of the key issues
is the use of the maximum tolerated dose, which can reach
35 mg/kg/day in order to obtain the best possible outcome.
One important issue regarding the use of HU is whether
such treatment can prevent the occurrence and recurrence of
strokes.
In a prospective study, 35 children who had suffered
strokes discontinued their red blood cell transfusion regimens
and started drug therapy with HU associated with serial
phlebotomy to reduce iron overload. The study showed a
reduction in the rate of recurrent strokes from 5.7 events/100
patient-years to 3.6 events/100 patient-years as well as
reduction in iron overload evaluated by serum ferritin levels
and liver biopsy. The authors concluded that HU partially
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prevents the occurrence of strokes and that serial phlebotomy
is capable of preventing transfusional iron overload.(30) (B)
In a Belgian study on the use of HU in SCD children at high
risk of strokes as detected by TCD, the CBFV decreased
significantly in 11 of 34 children with abnormal TCDs, and
only one developed a primary stroke over a follow-up of 96
patient-years.(19) (B)
Due to this data there was a consensus in the meeting
that HU therapy is an alternative to the blood transfusion
regimen particularly in situations where patients do not
comply with transfusion therapy.
Therapeutic approach to conditional
transcranial doppler
Recommendation: There is no scientific evidence to
recommend the use of HU in patients with conditional TCD.
The evaluation of the effects of HU on CBFV measured
by TCD in SCA children showed that medication use at the
maximum tolerated dose resulted in a significant decrease of
the velocities. After a year of full-dose treatment, the
following results were obtained from 15 children with
conditional values of velocities; the velocity decreased in
14; the velocities dropped below 200 cm/s in five of six
children with abnormal initial values at TCD and whose parents
had refused treatment by transfusions.(31) (B) In a cohort of
24 SCD patients, treatment with HU has shown to result in
average reductions in CBFV of 13.0 cm/s at TCD imaging.
Patients with untreated SCD constituted the control group
adjusted for age, in which the CBFV showed an increase of
4.72 cm/s (significant difference, p <0.001). Of the five patients
with velocities > 170 cm/s who were treated with HU, four
progressed to normal values, resulting in an average reduction
of 34.75 cm/s.(32) (C)
Considering the relative paucity of data relating to the
administration of HU in patients with conditional TCD, the
panel chose not to make any recommendation to use the
agent in this situation, although it was acknowledged that in
practice, this approach might be beneficial.
Conclusion
Early diagnosis and treatment have proven to increase
survival and improve quality of life of SCD patients. However,
achieving these goals is directly related to the organization
of a SCD patient care network in all Brazilian states, through
the formation of specialized reference centers capable of
providing global, multidisciplinary and multi-professional
services. Thus, the development of public policies and other
actions that consider the socioeconomic and cultural issues
and care related to SCD, as well as the commitment of
competent health agencies, healthcare professionals and
organizations that represent patients are key factors and
determinants to improve SCD patient care.
The Brazilian Guidelines on the use of transcranial
Doppler in Sickle Cell Disease Children and Adolescents
is an initiative of leading experts in the areas of diagnosis
and treatment of SCD, with the participation of those
responsible for public health agencies, national medical
societies, and institutions that representative SCD patients.
The adoption of these guidelines may result in a reduction
in the risk of strokes in this patient population as
demonstrated by scientific evidence, thereby helping to
reduce morbidity and mortality and to improve quality of
life of SCD patients.
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